An interventional study of Digital education outreach intervention for kidney transplant access and human guide and Digital education outreach intervention for kidney transplant access only (unguided) in End-Stage Renal Disease, Chronic Kidney Diseases and Kidney Transplant, sponsored by State University of New York at Buffalo. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by State University of New York at Buffalo · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 58th largest by planned enrollment of the 638 interventional ones that give a count, is one of 4 that started in 2027, is one of 287 with no phase, reaches primary completion later than 92 of the 95 other live ones, and was the 735th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 4 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 550 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 611 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
State University of New York at Buffalo has 2 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a 2-arm randomized controlled trial among patients referred for kidney transplant evaluation at a single transplant center to compare the effects of a digital-analog intervention to increase living-donor kidney transplant access (KT-CONNECT) versus usual care. Following consent and baseline assessment, participants are randomized with equal allocation to 2 treatment arms: the KT-CONNECT intervention or Usual Care
Over a 3-year period the investigators will conduct a pilot 2-arm parallel randomized trial among patients referred for kidney transplantation at a single transplant center to compare the effects of the intervention over 6 months of intervention use and follow-up.
Participants will be recruited from a single transplant program in the US. Each week, electronic records will be accessed to identify patients and their carers who present for transplant evaluation at the transplant center for a kidney transplant, are aged 18 years and older, speak English, and are competent to provide informed consent . The investigators will exclude patients previously exposed to any component of the intervention, listed for transplantation at another center, and seeking multiorgan transplantation.
A stakeholder Advisory Council, whose members include patients and care partners, will review and provide ongoing feedback on the recruitment and retention plan. They will also provide input on assistive dissemination tools for organizations to engage individuals to use the resource.
Each potential participant will be invited to the study by a researcher who will describe the study and answer and questions, and provide a copy of the consent form describing study procedures and potential risks.
Those who sign electronic consent to participate will be asked to complete a baseline sociodemographic and pre-test survey. Upon completion, computer-generated randomization will stratify participants by self-reported race (Black versus Other), with equal allocation to 2 treatment arms: the intervention or usual care. Condition assignment of each participant will be concealed from transplant providers, but participants will become aware of their treatment assignment once they access the intervention.
KT-CONNECT is a digital-analog intervention with human support. It is based on animated video education targeted to patients, donors, and support persons, designed to address knowledge gaps, confidence , and lack of tools to pursue kidney transplantation and living donation that were identified in literature reviews, formative research, and video development studies as critical for optimal prospective kidney recipient and donor participation in LDKT. Other key components include (1) personalized donor outreach materials, (2) email reminders about study resources, and (3) practical assistance to ensure access to intervention, and (4) advise use the intervention and encourage outreach actions. All components of the intervention were developed through a user-centered design approach by involving kidney failure patients and social network members, to improve reach, usability and increase the likelihood of uptake.
In both intervention and control arms, the investigators chose 6 videos from the entire series to be delivered sequentially for a total duration of 13 minutes. The video content sets the stage for the intervention and introduces the viewer to an overview of LDKT, including addressing common misconceptions about live kidney donation, donor eligibility, donor evaluation, kidney paired donation, donation costs, and donor recovery. After completing the proscribed videos everyone then receives weekly emails with links to the full video curriculum centralized on a website and other local resources. Email messages introduce study videos and features and local resources that may interest users, provide access links, and encourage video viewing and sharing. Messages will be personalized with the participants name and provide researchers contact information. The videos on the website are activated for sharing through various modalities, including text, email, Facebook, and Twitter. The website also contains templates and examples for other donor outreach materials and practical engagement materials to promote awareness of the website. The website is open access from any electronic device. Finally, at clinic appointments participants will receive practical assistance to use intervention materials.
In the intervention arm, donor outreach will be supported by telephonic human guides who will provide tailored implementation support in 7 areas that include ensuring access, advising use, recommending features, encouraging donor outreach, and referrals to clinical services, support groups, community resources. Human guides will interact with participants over a 6-month period.
Control participants will not receive the intervention.
All participants routinely receive educational materials from non-study sources through usual Transplant Center protocols including written materials and clinical provider communications. Providers may recommend the study website or individuals may find it on their own.
After completing the proscribed video education, all participants will be invited to fill out serial surveys at 3 months post-evaluation. Participants will receive up to 6 reminders (5 automatic and 1 personalized) to complete surveys. At study conclusion, participants may be invited to an exit interview.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
KT-CONNECT is a multicomponent mobile education-outreach intervention to increase patient- and network-to-donor self-learning and outreach, about living donor kidney transplantation. Human guide support offered over a 6 month period to encourage use of the intervention and donor outreach.
Behavioral: Digital education outreach intervention for kidney transplant access and human guide
Routine clinical support from non-study sources through usual Transplant Center protocols including clinic provider communications.
Behavioral: Digital education outreach intervention for kidney transplant access only (unguided)
Receives (1) donor search materials, (2) electronic resource access messages, (3) practical assistance to use the intervention and empower taking the outreach action and (4) telephonic human guide
Receives (1) donor search materials, (2) electronic resource access messages, and (3) practical assistance to use the intervention and empower taking the outreach action.
Living donor kidney transplant
Count of living donor transplants at the transplant center on behalf of the study participants within 18 months from enrollment. The transplant episode is counted and added to a discrete field for all patients in the electronic medical record.
Time frame: Baseline, post baseline 18 months
LDKT Perceived understanding
Developed specifically for this study as a measure of perceived understanding about LDKT as delivered in the intervention condition. In this 4 item 4-point Likert questionnaire, total scores range from 3-16 with higher scores indicating greater LDKT-related understanding. The scale captures different dimensions of understanding including kidney transplant navigation, awareness of services, donor outreach.
Time frame: Baseline, post baseline 3 months
LDKT Conversational self-efficacy
A 2-item survey testing confidence to communicate about LDKT with others. Items are rated on a scale of 1 to 4, total scores range from 2-8. Higher scores indicate greater confidence to communicate about LDKT with others.
Time frame: Baseline, post baseline 3 months
LDKT Beliefs scale
Developed specifically for this study as a measure of patients' beliefs about LDKT. Questions were drawn from existing measures in the literature. We created a 2-item scale. One item captured the degree to which a person believes that LDKT is an advantage. The other item assessed the degree to which a person believes their social network is healthy enough to donate a kidney. Items are rated on a scale of 1 to 4. Total scores range from 2-8 with higher scores indicate greater concerns about live kidney donation.
Time frame: Baseline, post baseline 3 months
Donor outreach behaviors
A measure of ongoing outreach toward living donor kidney transplantation. To assess LDKT action behaviors patients will be asked whether they had done any of 14 related behaviors adapted from existing measures in the literature. Patients who indicated they had done the action will be counted and scores will range from 0 to 14. Higher scores indicate more outreach.
Time frame: Baseline, post baseline 3 months
Living donor inquiry
Count of living donor inquires to the transplant center on behalf of the study participants within 18 months from enrollment. Each inquiry (telephone call, email, letter) is counted and added to a discrete field for all patients in the electronic medical record.
Time frame: Baseline, post-baseline at 18 months
Living donor evaluation
Count of living donor evaluations at the transplant center on behalf of the study participants within 18 months from enrollment. Each evaluation (at least one blood test or transplant provider consultation) is counted and added to a discrete field for all patients in the electronic medical record.
Time frame: Baseline, post baseline at 18 months
Time to waiting-list placement
The first time from evaluation to active placement on the kidney transplant waiting list will be assessed via medical record review.
Time frame: 18 months
Intervention Acceptability
16-item survey assessing intervention usage, ease of use, and usefulness. Each question has 4 Likert-scale options bounded by strongly agree and strongly disagree or multiple responses specific to the question. Total scores range from 16-64 with higher scores indicate greater intervention acceptability.
Time frame: Post-baseline 3 months
Patient perception of donor offer
A one item question asking participants if someone has agreed to donate a kidney to them, with the options of answering 'yes', 'no', or 'maybe'.
Time frame: Baseline, post baseline 3 months
Plan to share: No — No funding available for sharing
No publications or documents are linked to this record.
Start is estimated for Oct 2027; primary completion for Oct 2030, 36 months later.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jan 2027 → Oct 2027, primary completion Jan 2030 → Oct 2030 and completion Jul 2030 → Oct 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
State University of New York at Buffalo →